Tags : Option to Acquire

Takeda Exercises its Exclusive Option to Acquire PvP Biologics for

Shots: Takeda acquires PvP Biologics following the P-I proof-of-mechanism study of TAK-062 (Kuma062) to treat uncontrolled celiac disease. Takeda exercises its option to acquire by paying ~$330M as development & regulatory milestone including $35M up front In 2017, the companies collaborated to develop novel therapies for celiac disease, under which Takeda got exclusive option to […]Read More

Sarepta Exercises its Exclusive Option to Acquire Myngonexus Therapeutics for

Shots: Sarepta exercises its option to acquire Myonexus Therapeutics, in all stock transaction for $165M with its five Limb-girdle muscular dystrophy (LGMDs) gene therapies programs i.e LGMD2E, LGMD2D, LGMD2B, LGMD2L & LGMD2C In May,2018 Sarepta and Myonexus collaborated to develop and advance multiple gene therapy programs for LGMD, paying $60M upfront & milestones, gaining excsluive […]Read More